Peptide News Digest

#Sanofi

2 stories

Industry · View digest

Sanofi (NASDAQ: SNY) Reports Q2 2026 Earnings Thursday July 30 With Net Sales of €11.6 Billion (+17.8% at Constant Exchange Rates) Driven by Dupixent (+37.6% CER to €5.15 Billion) and New Pharma Launches (+48.3% CER to €1.3 Billion), Business EPS of €2.09 (+33.3% CER); Sanofi Discontinues Three Pipeline Assets in the Quarter (Amlitelimab OX40-Ligand mAb for Atopic Dermatitis With a €952 Million Intangible Impairment, Plus Itepekimab and Balinatunfib) and Raises Full-Year 2026 Guidance to Approximately 10% CER Sales Growth With Business EPS Growing Slightly Faster

Sanofi (NASDAQ: SNY) reported Q2 2026 earnings Thursday July 30, 2026 with net sales of €11,597 million (+17.8% at constant exchange rates, +16.0% at actual rates) and business EPS of €2.09 (+33.3% CER), both beating consensus. Growth drivers: Dupixent (dupilumab, IL-4/IL-13 receptor blocking antibody co-marketed with Regeneron) reached Q2 sales of €5,154 million (+37.6% CER); new pharma launches reached €1,305 million (+48.3% CER). Sanofi raised full-year 2026 guidance: sales now expected to grow approximately 10% at CER, with business EPS at CER expected to grow slightly faster than sales. Three pipeline discontinuations disclosed with the earnings release: amlitelimab (OX40-ligand monoclonal antibody previously advanced in atopic dermatitis after acquisition from Kymab; the intangible asset was impaired by €952 million with an announced decision that the drug would not represent a substantial improvement to the standard of care), itepekimab (IL-33 antibody previously advanced in COPD, chronic urticaria, and other Type 2 inflammation indications), and balinatunfib. Stock reaction was mixed with Sanofi shares slipping in premarket trading on the pipeline setbacks despite the earnings beat.

Clinical Trials · View digest

FDA Approves Sanofi's Tzield (Teplizumab) for Children Down to Age 1 in Stage 2 Type 1 Diabetes — First Disease-Modifying Therapy for Pediatric T1D

Sanofi announced April 22 FDA approval of an expanded Tzield (teplizumab-mzwv) indication for stage 2 type 1 diabetes patients as young as 1 year old, down from the previous 8-and-up indication. The approval was supported by 1-year data from the PETITE-T1D Phase 4 study (n=23, mean age 4.8 years), showing 89.6% probability of remaining stage-3-progression-free at 1 year. Tzield delays progression from stage 2 to stage 3 T1D by an average of 2 years and is the first disease-modifying therapy for autoimmune T1D — relevant to the broader insulin/peptide endocrinology landscape.